4/19/2016 CAPA | CAPAS: Too Much or Not Enough? | Pharmaceutical Manufacturing

http://www.pharmamanufacturing.com/articles/2008/047/?show=all 1/9

LOGIN | REGISTER

Print Email Tweet

A A A A +

Home / Articles / 2008 / CAPAS: Too Much or Not Enough?

CAPAS: Too Much or Not Enough?A strategic CAPA plan requires transparent information and a clear understanding of rootcauses.Mar 25, 2008

Corrective and Preventive Action (CAPA) is a critical part of pharmaceutical quality systems. Failure tocomply with requirements can be costly for any pharmaceutical or biopharma company, resulting indamaged reputation and profitability. But adhering to CAPA is not only a regulatory requirement — it’s soundbusiness practice. This article examines issues and presents best practices.

FACT: CAPA continues to top citations for 483s and warning letters for pharmaceutical companies.

FACT: Despite the progress being made in ICH Q10 Quality Systems discussions and other frameworks,during the past two years, an increasing number of pharmaceutical quality issues and recalls have madenewspaper headlines. Have pharmaceutical CAPA programs evolved, and are they moving in the rightdirection?

From a regulatory perspective, CAPA implementation and effectiveness is a key indicator of overall QualitySystems effectiveness, yet many drug companies still struggle to achieve and maintain compliance. Theoverarching reason is that many facilities and companies are still using a variety of manual, semiautomatedand homegrown systems.

Smallerscale reasons include the following: CAPA is an independent piece of the quality system and oftenviewed as “Quality’s job.”

MENU

Share Share

4/19/2016 CAPA | CAPAS: Too Much or Not Enough? | Pharmaceutical Manufacturing

http://www.pharmamanufacturing.com/articles/2008/047/?show=all 2/9

In some cases, an organization’s processes are fragmented and disconnected.

Procedures are not always well documented.

Required process steps are not always completed.

Employees don’t always know or understand their individual level of responsibility or authority.

Not all source inputs to potential nonconformances are identified.

Information is not measured, monitored or shared across different product lines or business units.

Trending data are not always visible to the appropriate level in the organization.

Companies tend to neglect to look into the processes and procedures of their quality systems. Theirfocus is on product rather than the efforts to resolve systemic issues, or they fastforward to a solutionwithout really identifying the root cause.

For all these reasons, pharmaceutical companies can have difficulty following and enforcing standards andconsistent procedures, or using trending data that is visible to the entire organization, to predict qualityacross all products and processes. In many facilities or companies, there is no realtime visibility ofcompliance and quality activities.

Moreover, a lack of good reporting and trending capabilities makes it difficult for top management to makeaccurate assessments about the issues, risks and especially costs facing the organization. Not onlydisconnected systems, but a lack of fully closedloop processes across key compliance systems can preventpharmaceutical manufacturers from harnessing the data that would minimize surprises and give them anearly warning of impending problems.

How can pharmaceutical companies improve their CAPA systems? The first step toward improvement isthinking about CAPA holistically, and recruiting and training the employees who will operate the system. Aneffective CAPA management system revolves around a global program, trained employees, welldocumented SOPs and proper utilization of technology to institute global practices and procedures.

Focal Points Planning – The foundation of a successful CAPA system is adequate planning and setup.Before establishing a CAPA system, you need to define code rules and ownership. The following questionsneed to be addressed:

What are the rules and variances to the rules?

What are the processes and who are the owners?

What will the failure modes be?

How will severity levels be defined?

Who will enter the information?

Remember that the nonconformance control/CAPA system should be scalable, simple, riskbased, andeasily integrated throughout the organization. Ensure that sufficient mechanisms are in place so that allsteps are completed for each event. It’s very important that you determine whom to involve in the CAPAprocess and when.

You will need to decide how procedure revisions will be handled and how you will enforce rules andprocedures on a global level.

Source Error Tracking – Many companies may lack connected data sources. At numerous others, the

4/19/2016 CAPA | CAPAS: Too Much or Not Enough? | Pharmaceutical Manufacturing

http://www.pharmamanufacturing.com/articles/2008/047/?show=all 3/9

crossreferencing of source errors, deviations and other events across files, dates, batch lots and othercriteria is done by hand, requiring a significant amount of time and creating opportunities for impacts andtrends to be missed. This approach leads to serious inefficiencies and continued repetition of mistakes.

The first step is to identify, collect and record any information that can occur anywhere throughout yourproduct or process’s value chain. You will need to identify everything from problems that may occur atbusiness partners’ sites, through the final manufacturing, labeling and distribution life cycle to any possiblecustomer complaints. The key to recording problems is to drive to the root cause and focus on preventionand correction actions. The more knowledge you have, the faster you can react. Tracking problems will allowyou to develop best practices and verify effectiveness.

The system may build upon existing infrastructure, but eventually all data should be routed to one location.Without an integrated system, identifying root causes is little more than guesswork. Assumptions are madebased on rumor and conjecture, rather than accurate, reliable data. Islands of information created bymultiple data streams lead to inconsistencies and waste. Real measuring tools enable managers todetermine precisely where and when mistakes are occurring and why.

A sole repository of information for the organization, which includes external and internal inputs from productlife cycle, processes and quality systems, ensures that supervisors and managers can quickly accessinformation, compare and contrast solutions to determine best practices, and monitor overall performance. Inother words, when a company has a closedloop nonconformance control and CAPA system, with a fewclicks of the mouse, a manager can see what’s happening companywide, rather than having to reviewmultiple documents and files.

Trending, Analysis and Risk Management – Once sourceerror information is correctly captured, manycompanies escalate these immediately to CAPAs to begin the investigation process. This behavior, enforcedby FDA on good investigations and by the company’s own internal policies to close CAPAs within a shorttime period, may lead to an overload of data that doesn’t inherently reveal the critical impact of what’s failingacross the organization.

With a volume of CAPAs, a company can become too overwhelmed to assure the effectiveness of itsCorrective/ Preventive action plans; to determine what the trending actually shows; and if the informationprovided back to product design is going anywhere. Use the data you collect to detect minor problemsquickly before they become major problems. Change the behavior of your employees by applying risktechniques throughout the CAPA program.

The progress of risk management has been seen in many companies that have implemented risk mitigationplans and assessed failures as part of the overall product formulation and development cycle. However,such risk techniques have been left to the front or back part of the process, leaving each designateddepartment (QA/Manufacturing, R&D) to track, trend or analyze data individually. Progressive companiesneed to adopt and integrate risk techniques as part of the nonconformance and CAPA process to correctlycategorize and prioritize those critical problems: focus.

For these critical CAPAs, the company’s Risk Management Team should be integrated into the investigationand root cause analysis process of the CAPA itself, where analysis shouldn’t be left to just product but alsoprocess, therapy and users/usage (route of administration). This will help increase the view of criticalproblems to management and help each department focus on the key areas of impact for both effectivenessand overall product and process improvement, moving an organization from reactive to proactive.

Trending is still a key within an organization to monitor the pulsepoint of an organization’s overall health ofits quality systems. Implement measurement, data analysis tools, and processes for different levels of theorganization. Assure that there are linkages within between products, processes, quality systems, and

4/19/2016 CAPA | CAPAS: Too Much or Not Enough? | Pharmaceutical Manufacturing

http://www.pharmamanufacturing.com/articles/2008/047/?show=all 4/9

across multiple divisions and/or facility locations. Configure data such that problems related to product,process, or the quality system can be identified and acted upon quickly. Leverage as much information aspossible to draw targets and assess effectiveness. Harmonization of sources, failure and root cause codes isessential to drawing meaningful conclusions.

Results of the analysis and/or any further decision to take action are identified as an output of thenonconformance/CAPA system. Change can be a result of a CAPA process or a part of your continuousimprovement initiative. Regardless, by taking the information you have gathered and analyzing it, you areable to detect areas where you can improve and change. The CAPA process should be tied to a company’soverall change management strategy to more effectively respond to issues as they arise.

Employee Accountability and Management Visibility – Drive for employee understanding and ownership(accountability) by implementing consistent and sustainable practices and a tiered training program. Trainemployees at all levels of the organization, and across departments, on sound investigation methods, gooddocumentation techniques, and the meaning/purpose of all CAPA elements. Management can encourageemployees to embrace quality throughout the organization by instigating new programs.

Provide a bonus for compliance factors:

Timely implementation and documentation of CAPA

No 483 observations

Getting (or keeping) the CE mark Alternatively, institute a disciplinary system for noncompliance:

Letters of reprimand for not meeting commitments

Dismissal for repeated failure to comply

Closedloop CAPA processes allow management to see where the problems exist across their organizationsand how effective their current processes are. When fully integrated into an organization, a closedloopCAPA system can positively affect operational performance and move organizations from a reactive postureto a more proactive one.

The focus of such a system is prevention and correction of deviations, which in turn reduces bad batches,generates fewer regulatory warnings and recalls, and boosts company profits and customer satisfaction. Inaddition, with the data you collect, you can monitor the cost of quality and provide key metrics tomanagement to help justify further investments in CAPA and global quality systems.

Quantify the cost of noncompliance by calculating:

Waste

Customer complaints

Corrections and recalls

Delays in IND and NDA clearance

Suspension of government contracts

Not getting certificates for product for export

Shutting down of your operations

Product liability actions

Shareholder lawsuits

4/19/2016 CAPA | CAPAS: Too Much or Not Enough? | Pharmaceutical Manufacturing

http://www.pharmamanufacturing.com/articles/2008/047/?show=all 5/9

Such trending of data can not only help you with improvements but also help the organization realize thatpreventive action is cheaper than corrective action. It’s all about the business More and more companies areadopting continuous process improvement and implementing closedloop, integrated CAPA across theenterprise. A constant flow of information across your value chain can reduce time to diagnose and resolveproblems, avoid supplier shortfalls, and help to meet customer expectations.

The collaboration that is required to bring products to market faster and safer, avoid regulated actions andimprove customer satisfaction demands an integrated CAPA system to plan and manage all variability, risksand visibility. Close the circle of quality assurance by developing, implementing, and maintaining a closedloop CAPA system that integrates compliance into business practices and quality systems. Use your CAPAsystem to improve profitability by decreasing the cost of quality. High cost of quality impacts the bottom line(waste, delays in product approval, resource inefficiency, etc.).

Drive actions based on data and risk in order to help determine where to focus actions and resources. Bydetecting and reducing errors across the enterprise, quality and therefore customer safety improves. A welldeveloped CAPA process is critical to reducing risk, improving customer satisfaction, reducing variability, andkeeping product quality visible across the organization.

About the Author

Nikki Willett is vice president of Marketing & Regulatory Products at Pilgrim Software.

Show Comments